ReviewFrontiers in allergy2026
Epigenetics in asthma: implications for treatable traits.
Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic mechanisms refer to heritable and potentially reversible modifications that regulate chromatin architecture and gene expression without altering the underlying DNA sequence. In asthma, these mechanisms provide a molecular interface between genetic susceptibility, environmental exposures, and immune dysregulation, contributing to disease heterogeneity and treatment response. The treatable traits paradigm, which focuses on the identification of specific modifiable biological and clinical characteristics, offers a clinically relevant framework for linking epigenetic changes to distinct molecular endotypes, enhancing mechanistic stratification beyond traditional phenotyping, thereby supporting precision medicine approaches. Emerging evidence suggests that epigenetic signatures have considerable potential as biomarkers for inflammatory endotyping and therapeutic stratification, although further validation is required before routine clinical implementation. In this mini review we will discuss epigenetic mechanisms involved in the development and maintenance of asthma processes, such as DNA methylation, histone modifications, and noncoding RNAs, focusing on their relevance to key treatable traits, including type 2 inflammation, corticosteroid responsiveness, airway remodeling, and exposure-driven disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.